Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
03 12월 2022 - 4:00AM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that the company has ranked No. 4 on the Boston Globe’s
2022 Top Places to Work in the “Large Companies” category, marking
its fourth consecutive year as an honoree.
The Boston Globe’s Top Places to Work, which will be featured in
the print edition of Sunday’s paper, recognizes the most admired
workplaces in the state, voted on by the people who know them best
– their employees. The survey measures employee opinions about
their company's leadership, appreciation, benefits and more. The
winners are divided into four categories based on the number of
employees: small (50-99); medium (100-249); large (250-999); and
largest (1,000 or more). More than 94,000 employees at 381
companies completed surveys this year—a record high.
“At Beam, our vision is to provide life-long cures for patients
suffering from serious diseases, and the ‘Beam Team’ is not only
committed to making breakthroughs happen; they are committed to
making Beam an exciting place to work, motivating colleagues and
building a strong company culture in the process,” Susan O’Connor,
chief human resource officer at Beam. “We are proud to be named,
for the fourth year in a row, to this prestigious list of companies
is Massachusetts who are committed to their missions, and
importantly, each other.”
As an employer of choice, Beam is committed to fostering a
culture that encourages employees to engage with colleagues. The
company’s culture team frequently hosts programs on wellness,
community engagement, diversity and inclusion, and team building to
inspire, educate and care for employees. Events like Beam’s annual
summer party, various walks and events in support of patient
advocacy groups (including Light the Night and Walk with the Stars)
and its “Balance @ Beam” wellness program supporting mental and
financial health, demonstrate the company’s commitment to creating
a culture that allows employees to thrive. Beam’s extensive
benefits package includes programs like its "Take It as You Need
It" paid time off policy, a five-week paid sabbatical after five
years with an additional $5,000 stipend, medical benefits, a health
and fitness reimbursement, 401k retirement plan, commuter
reimbursement, family-forming benefits, an employee referral
program and student loan refinancing.
In addition to its recognition as one of the Top Places to Work,
Beam was named to the 2022 Best Places to Work list by the Boston
Business Journal. For more information on careers at Beam, please
visit https://beamtx.com/careers/.
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that is designed to enable
precise, predictable and efficient single base changes, at targeted
genomic sequences, without making double-stranded breaks in the
DNA. This has the potential to enable a wide range of potential
therapeutic editing strategies that Beam is using to advance a
diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024